{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:54:50Z","timestamp":1794074090534,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chilean National Fund for Scientific and Technological Development","award":["11150802"],"award-info":[{"award-number":["11150802"]}]},{"name":"Chilean National Fund for Scientific and Technological Development","award":["11150622"],"award-info":[{"award-number":["11150622"]}]},{"name":"Chilean National Fund for Scientific and Technological Development","award":["1130204"],"award-info":[{"award-number":["1130204"]}]},{"name":"Chilean National Fund for Scientific and Technological Development","award":["1151008"],"award-info":[{"award-number":["1151008"]}]},{"name":"Chilean National Fund for Scientific and Technological Development","award":["15130011"],"award-info":[{"award-number":["15130011"]}]},{"DOI":"10.13039\/501100013928","name":"Millennium Institute on Immunology and Immunotherapy","doi-asserted-by":"crossref","award":["P09- 016-F"],"award-info":[{"award-number":["P09- 016-F"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009465","name":"Production Development Corporation","doi-asserted-by":"crossref","award":["12IDL2-18157"],"award-info":[{"award-number":["12IDL2-18157"]}],"id":[{"id":"10.13039\/100009465","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009465","name":"Production Development Corporation","doi-asserted-by":"crossref","award":["09CN14-5960"],"award-info":[{"award-number":["09CN14-5960"]}],"id":[{"id":"10.13039\/100009465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.prp.2017.01.025","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T03:05:38Z","timestamp":1487905538000},"page":"476-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The ERK\/MAPK pathway is overexpressed and activated in gallbladder cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Kurt","family":"Buchegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Brebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2017.01.025_bib0005","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjsurg.2007.11.011","article-title":"Gallbladder cancer","volume":"196","author":"Gourgiotis","year":"2008","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.prp.2017.01.025_bib0010","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"August(7)","key":"10.1016\/j.prp.2017.01.025_bib0015","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/PAI.0b013e3182a318a9","article-title":"Immunohistochemical expression of vascular endothelial growth factor a in advanced gallbladder carcinoma","volume":"22","author":"Letelier","year":"2014","journal-title":"Appl. Immunohistochem. Mol Morphol."},{"key":"10.1016\/j.prp.2017.01.025_bib0020","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(03)01021-0","article-title":"Carcinoma of the gallbladder","volume":"4","author":"Misra","year":"2003","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.prp.2017.01.025_bib0025","first-page":"1540","article-title":"Gallbladder cancer in a high risk area: morphological features and spread patterns","volume":"46","author":"Roa","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.prp.2017.01.025_bib0030","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: cholelithiasis and cancer","volume":"6","author":"Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.prp.2017.01.025_bib0035","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","article-title":"Epidemiology and molecular pathology of gallbladder cancer","volume":"51","author":"Lazcano-Ponce","year":"2001","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.prp.2017.01.025_bib0040","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/ijms17050791","article-title":"Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers","volume":"17","author":"Letelier","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2017.01.025_bib0045","first-page":"1","article-title":"Implication of miRNAs in the Pathogenesis of Gallbladder Cancer","volume":"2","author":"Letelier","year":"2015","journal-title":"Austin Biomarkers Diagn."},{"key":"10.1016\/j.prp.2017.01.025_bib0050","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2015.329","article-title":"Stamping out RAF and MEK1\/2 to inhibit the ERK1\/2 pathway: an emerging threat to anticancer therapy","volume":"35","author":"Mandal","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.01.025_bib0055","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","article-title":"How ERK1\/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?","volume":"8","author":"Mebratu","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.prp.2017.01.025_bib0060","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","article-title":"The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","volume":"26","author":"Meloche","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.01.025_bib0065","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ajpath.2012.02.028","article-title":"MAPK\/ERK-dependent translation factor hyperactivation and dysregulated laminin \u03b32 expression in oral dysplasia and squamous cell carcinoma","volume":"180","author":"Degen","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prp.2017.01.025_bib0070","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"key":"10.1016\/j.prp.2017.01.025_bib0075","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1023\/A:1023781114568","article-title":"Role of MAP kinase in tumor progression and invasion","volume":"22","author":"Reddy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.prp.2017.01.025_bib0080","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00535-007-2055-7","article-title":"Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer","volume":"42","author":"Hori","year":"2007","journal-title":"J. Gastroenterol."},{"issue":"July(7)","key":"10.1016\/j.prp.2017.01.025_bib0085","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00535-015-1145-1","article-title":"A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks","volume":"51","author":"Mohri","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.prp.2017.01.025_bib0090","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1756-9966-28-65","article-title":"Expression of phospho-ERK1\/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations","volume":"28","author":"Li","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2017.01.025_bib0095","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/ijc.23662","article-title":"Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study","volume":"123","author":"Andia","year":"2008","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.prp.2017.01.025_bib0100","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/ijc.25421","article-title":"Gallbladder cancer: incidence and survival in a high-risk area of Chile","volume":"127","author":"Bertran","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2017.01.025_bib0105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5858\/arpa.2011-0628-OA","article-title":"Connective tissue growth factor immunohistochemical expression is associated with gallbladder cancer progression","volume":"137","author":"Garcia","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2017.01.025_bib0110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00428-014-1588-4","article-title":"The PI3K\/AKT\/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance","volume":"465","author":"Tapia","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2017.01.025_bib0115","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.seminoncol.2006.04.002","article-title":"Role of Raf kinase in cancer: therapeutic potential of targeting the Raf\/MEK\/ERK signal transduction pathway","volume":"33","author":"Gollob","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.prp.2017.01.025_bib0120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.01.008","article-title":"Mutant BRAF melanomas-dependence and resistance","volume":"19","author":"Poulikakos","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2017.01.025_bib0125","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.prp.2017.01.025_bib0130","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2017.01.025_bib0135","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ni0405-368","article-title":"MAPK p38: alternative and nonstressful in T cells","volume":"6","author":"Rudd","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2017.01.025_bib0140","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","article-title":"Blocking oncogenic Ras signaling for cancer therapy","volume":"93","author":"Adjei","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2017.01.025_bib0145","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.01.025_bib0150","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1038\/sj.onc.1207556","article-title":"Mitogen-activated protein kinases in apoptosis regulation","volume":"23","author":"Wada","year":"2004","journal-title":"Oncogene."},{"key":"10.1016\/j.prp.2017.01.025_bib0155","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.prp.2017.01.025_bib0160","first-page":"387","article-title":"Morphological prognostic elements in gallbladder cancer","volume":"130","author":"Roa","year":"2002","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.prp.2017.01.025_bib0165","first-page":"1373","article-title":"AKT\/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines","volume":"6","author":"Leal","year":"2013","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.prp.2017.01.025_bib0170","doi-asserted-by":"crossref","first-page":"31877","DOI":"10.18632\/oncotarget.5047","article-title":"Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice","volume":"6","author":"Weber","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2017.01.025_bib0175","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1186\/s12885-015-1855-z","article-title":"Macrophage migration inhibitory factor \u2013 a therapeutic target in gallbladder cancer","volume":"15","author":"Subbannayya","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2017.01.025_bib0180","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.prp.2017.01.025_bib0185","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-4827(02)00099-X","article-title":"The ErbB receptors and their role in cancer progression","volume":"284","author":"Holbro","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.prp.2017.01.025_bib0190","doi-asserted-by":"publisher","first-page":"7620","DOI":"10.1074\/jbc.271.13.7620","article-title":"An immunological approach reveals biological differences between the two NDF\/heregulin receptors, ErbB-3 and ErbB-4","volume":"271","author":"Chen","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2017.01.025_bib0195","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1073\/pnas.91.4.1500","article-title":"Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation","volume":"91","author":"Qian","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2017.01.025_bib0200","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","article-title":"Dimerization of cell surface receptors in signal transduction","volume":"80","author":"Heldin","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.prp.2017.01.025_bib0205","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2017.01.025_bib0210","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF\u2013ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1016\/j.prp.2017.01.025_bib0215","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.01.025_bib0220","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.trecan.2015.10.001","article-title":"Targeting RAS-mutant Cancers: Is ERK the Key?","volume":"1","author":"Ryan","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.prp.2017.01.025_bib0225","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1476-4598-13-105","article-title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment","volume":"13","author":"Ma","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2017.01.025_bib0230","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.1073\/pnas.1518361112","article-title":"Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration","volume":"112","author":"Lee","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2017.01.025_bib0235","first-page":"43","article-title":"MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy","volume":"10","author":"Tran","year":"2016","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033816306501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033816306501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:35:14Z","timestamp":1589718914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033816306501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0344033816306501"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2017.01.025","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ERK\/MAPK pathway is overexpressed and activated in gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2017.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}